Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL1107 vs Timolol in Primary Open Angle Glaucoma or Ocular Hypertension
NCT07168902Phase 2Completed
- Sponsor
- Bausch + Lomb
- Start
- Oct 2025
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BL1107 in Glaucoma and ocular hypertension (3 arms), sponsored by Bausch + Lomb. Primary endpoint: Change from baseline in visual field mean deviation at 28 days. Started Oct 2025; status: completed.
02
Drugs
BL1107
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT07168902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168902.